VJOncology is committed to improving our service to you

ESMO 2018 | Limiting duration of treatment with checkpoint inhibitors: the data

VJOncology is committed to improving our service to you

Jeffrey Weber

Jeffrey Weber, MD, PhD, of the Perlmutter Cancer Center, New York, NY, discusses the latest clinical trials and explores the comparative efficacy of single agent and combination therapy for melanoma involving checkpoint inhibitors. Dr Weber concludes the interview, indicating the application of a Positron Emission Tomography (PET) scan in patients 1-2 years into checkpoint inhibitor therapy, to determine the safety of the treatment. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter